ClinicalTrials.gg
Not yet recruitingNCT07947511Updated Nov 19, 2026

Oral-Challenge Study: Steady-State High-ORP Water/Gel Relieves AITC- and Capsaicin-Induced Oral Pain in Healthy Volunteers

An interventional study of Stabilized 780±21 mV High-Oxidation-Potential Water in Oral Mucosal Pain, Oral Mucosal Irritation and TRPA1-Mediated Pain, sponsored by Dove Medical Press Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Dove Medical Press Ltd · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 247 studies in Pain with a site in China — 66 open to participants now, 72 under way, 2 of them phase 3. Pain · China.

Planned enrollment
195th of 212
24 · median 120
Started
2026
with 24 others
No phase
117 of 247
40 open now
Primary completion
2026-12
later than 32 of 71 live
Registered
246th of 247
by date

Among the 247 studies in Pain with a site in China, this one is the 195th largest by planned enrollment of the 212 interventional ones that give a count, is one of 25 that started in 2026, is one of 117 with no phase, reaches primary completion later than 32 of the 71 other live ones, and was the 246th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

66 of the 247 studies in Pain with a site in China are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Pain with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of stabilized 780±21 mV high-oxidation-potential water to rapidly relieve oral mucosal pain and irritation induced by AITC (wasabi-horseradish) and capsaicin (chili-oil), which activate TRPA1 and TRPV1 sensory ion-channels. Healthy volunteers receive oral 40 mL stabilized high-oxidation-potential water after oral irritant challenge. Pain-irritation NRS scores are assessed at baseline, 3 seconds, 30 seconds, 60 seconds, 120 seconds post-treatment. Safety observations are recorded throughout the study.

Read the detailed description

This is prospective, single-arm, open-label exploratory pilot study in healthy adult volunteers. Two separate oral irritant challenge models are applied: AITC-containing horseradish-wasabi challenge for TRPA1-mediated oral irritation-pain; capsaicin-containing chili-oil challenge for TRPV1-mediated burning oral pain. Total target enrollment is 24 healthy subjects (12 male,12 female). After irritant exposure, subjects take 40 mL stabilized 780±21 mV high-oxidation-potential water, hold in mouth then swallow. Subject-reported 0-10 NRS pain-irritation scores are collected at pre-challenge baseline; post-irritant baseline; 3 s,30 s,60 s,120 s after study product administration. Local oral-mucosal adverse reactions and systemic tolerability are monitored. Pre-existing rabbit ocular-surface safety testing supports mucosal safety of this formulation. This trial focuses on acute seconds-range symptom relief in experimental irritant-pain models.

03

Conditions studied

  • Oral Mucosal Pain
  • Oral Mucosal Irritation
  • TRPA1-Mediated Pain
  • TRPV1-Mediated Pain

Browse trials for

Keywords

  • high-oxidation-potential water; TRPA1
  • TRPV1
  • oral mucosal irritation
  • AITC
  • capsaicin
  • acute orofacial pain
  • sensory ion channel
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult volunteers aged 18-60 years old, male and female.
  2. Body weight range 40 kg-72 kg.
  3. No active oral-pharyngeal disease, no oral ulcer, gingivitis, pharyngitis at screening.
  4. Able to understand trial procedure, independently complete NRS numeric rating scale assessments.
  5. Voluntarily provide written .

Exclusion criteria

Exclusion Criteria:

  1. Active oral ulcer, stomatitis, gingival-periodontal acute disease, active pharyngitis.
  2. Known to electrolyzed saline / study formulation components.
  3. Gastro-esophageal reflux disease, active gastrointestinal disorder.
  4. Pregnant or lactating women.
  5. Recent consumption (\<72 hours) of large-dose spicy / irritant food interfering with pain perception.
  6. Concurrent participation in other oral-pain or mucosal-related clinical research.
  7. Psychiatric condition impairing study compliance.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Stabilized High-Oxidation-Potential Oral Water

    Other: Stabilized 780±21 mV High-Oxidation-Potential Water

Interventions

  • OtherStabilized 780±21 mV High-Oxidation-Potential Water

    Intervention description: Stabilized electrolyzed saline water with oxidation-potential 780±21 mV. After oral irritant challenge (AITC-horseradish-wasabi or capsaicin-chili-oil), subject takes 40 mL of study liquid, holds in oral cavity briefly then swallow, single administration for each challenge test.

06

What researchers measure

Primary outcomes

  1. AITC-Induced Oral Pain-Irritation NRS Score

    Participant self-reported 0-10 numerical rating scale for oral pain, stinging, choking-irritation triggered by AITC-containing horseradish-wasabi; 0 = no pain/irritation, 10 = worst imaginable oral irritation-pain.

    Time frame: Post-irritant baseline, 3 seconds, 30 seconds post-product administration.

  2. Capsaicin-Induced Oral Burning-Pain NRS Score

    Participant self-reported 0-10 NRS for burning-pain triggered by capsaicin-containing chili-oil; 0 = no burning-pain,10 = worst imaginable burning-pain.

    Time frame: Post-irritant baseline, 3 seconds, 30 seconds, 60 seconds,120 seconds post-product administration.

Secondary outcomes

  1. Participant Overall Subjective Relief Assessment Score

    Subject-rated 0-10 scale for overall subjective relief of oral discomfort after each challenge test;0=no relief,10=complete relief.

    Time frame: 120 seconds after product administration for each irritant challenge.

  2. Incidence of Adverse Events

    Incidence of product-related adverse events including oral mucosal stinging, numbness, gastrointestinal upset, throat irritation, nausea.

    Time frame: Throughout entire study visit period (within 30 minutes of product exposure).

07

Study locations

1 site
  • Hynaut Laboratory
    Qingdao, Shandong 266000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 1 month is below that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Dec 22, 2026
CompletionEst.
Jan 10, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947511
Lead sponsor
Dove Medical Press Ltd
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Dec 22, 2026 (estimated)
Completion
Jan 10, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Mizhou Hui
Contact
mizhou.hui@alumni.utoronto.ca
13484005199

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion